Phreesia, Inc. (NYSE:PHR) SVP Sells $34,885.71 in Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 1,311 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $34,885.71. Following the sale, the senior vice president now owns 115,633 shares of the company’s stock, valued at $3,076,994.13. This represents a 1.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total value of $532,605.71.

Phreesia Stock Up 5.3 %

NYSE:PHR traded up $1.44 during trading hours on Wednesday, hitting $28.42. The company’s stock had a trading volume of 668,317 shares, compared to its average volume of 410,783. The stock has a market capitalization of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average of $22.30 and a 200-day moving average of $22.49. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $29.16.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.58) earnings per share. On average, equities analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in Phreesia by 8.4% during the second quarter. Bank of New York Mellon Corp now owns 214,430 shares of the company’s stock worth $4,546,000 after buying an additional 16,614 shares during the period. Rhumbline Advisers grew its position in Phreesia by 1.0% during the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after purchasing an additional 853 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Phreesia in the second quarter valued at $301,000. Sei Investments Co. raised its holdings in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after buying an additional 95,058 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in shares of Phreesia by 3.2% during the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after buying an additional 700 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PHR shares. JMP Securities reissued a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird cut their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $24.00 to $32.00 in a report on Wednesday. Finally, KeyCorp increased their price target on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $30.64.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.